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Abstract
Fe-filled carbon nanotubes (Fe@CNTs) recently emerged as an effective class
of hybrid nanoparticles for biotechnological applications, such as magnetic cell
sorting and magnetic fluid hyperthermia. Aiming at studying the effects of both the
Fe loading and the magnetocrystalline characteristics in these applications, we
describe herein the preparation of Fe@CNTs containing different Fe phases that,
upon functionalization with the antibody Cetuximab (Ctxb), allow the targeting
of cancer cells. Our experimental findings reveal that an optimal Ctxb/Fe weight
ratio of 1.2 is needed for efficient magnetic cell shepherding, whereas enhanced
MFH-induced mortality (70 vs. 15%) can be reached with hybrids enriched in the
coercive Fe3C phase. These results suggest that a synergistic effect between the
Ab loading and the Fe distribution in each nanotube exists, for which the maximum
shepherding and hyperthermia effects are observed when higher densities of
Fe@CNTs featuring the more coercive pha...
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Biotechnological promises of Fe-ﬁlled CNTs for
cell shepherding and magnetic ﬂuid hyperthermia
applications†
Florent Pineux,a Riccardo Marega,a Antoine Stopin,a Alessandro La Torre,b
Yann Garcia,c Eamonn Devlin,d Carine Michiels,e Andrei N. Khlobystovb and
Davide Bonifazi*a,f
Fe-ﬁlled carbon nanotubes (Fe@CNTs) recently emerged as an eﬀective class of hybrid nanoparticles for
biotechnological applications, such as magnetic cell sorting and magnetic ﬂuid hyperthermia. Aiming at
studying the eﬀects of both the Fe loading and the magnetocrystalline characteristics in these appli-
cations, we describe herein the preparation of Fe@CNTs containing diﬀerent Fe phases that, upon
functionalization with the antibody Cetuximab (Ctxb), allow the targeting of cancer cells. Our experi-
mental ﬁndings reveal that an optimal Ctxb/Fe weight ratio of 1.2 is needed for eﬃcient magnetic cell
shepherding, whereas enhanced MFH-induced mortality (70 vs. 15%) can be reached with hybrids
enriched in the coercive Fe3C phase. These results suggest that a synergistic eﬀect between the Ab
loading and the Fe distribution in each nanotube exists, for which the maximum shepherding and
hyperthermia eﬀects are observed when higher densities of Fe@CNTs featuring the more coercive phase
are interfaced with the cells.
1. Introduction
Cancer nanotechnology, i.e. the use of nanoparticles as versa-
tile tools to diagnose and treat cancer, emerged in the past
decade as a complementary approach to the classical cancer
theranostics.1 Scientists have shown that nanostructured
materials can represent an eﬀective multifunctional platform
for targeting tumour tissues2,3 and to locally deliver thera-
peutic or imaging agents.4 Among the diﬀerent kinds of nano-
particles, carbon nanotubes (CNTs) have emerged as eﬀective
platforms for cancer theranostics both in in vitro and in vivo
studies.5–16
From the structural point of view, the interior cavities of
CNTs are exceptional frameworks to confine functional,
chemical17–19 and bioactive20 molecular species. For instance,
radioactive salts21 like Na125I or toxic Gd3+-based contrast
agents22–25 could be safely encapsulated and used in vivo as
responsive probes for imaging applications. Alternatively, mag-
netic nanoparticles (MNPs) utilised for magnetic resonance
imaging (MRI),26 magnetic fluid hyperthermia (MFH)27 or
magnetically-driven delivery,28 have also been confined inside
CNTs (MNPs@CNTs).29 These materials retain their magneto-
crystallinity for years,30 as the confinement procures protection
against oxidation reactions31,32 and consequent transform-
ation into less-performing magnetic phases.33 For example,
CNTs entrapping Ni catalyst residues have been proposed for
in vitro magnetically-driven DNA delivery in mammalian cells
(also known as “CNT spearing”).34 Similarly, low-content
Fe-filled CNTs (around 2.5 Fe wt%) were used by Vittorio et al.
to manipulate, by means of an external field,35 neuroblastoma
cells36 or mesenchymal stem cells in vivo.37 Additionally,
Fe@CNTs non-covalently coated with pluronic F127 have given
promising outcomes as dual MRI contrast agents and laser-
induced thermo-active therapeutic platforms.38 In this respect,
we recently reported39 on the functionalisation of Fe@CNTs
(prepared via the floating-catalyst chemical vapour deposition,
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FC-CVD, protocol40,41 for Fe loading >15 wt%) with cetuxi-
mab,42 an antibody (Ab) targeting the epidermal growth factor
receptor (EGFR) overexpressed in cancer cells. In vitro investi-
gations under a static magnetic field showed that this material
undergoes fast translation responses allowing us to sort
EGFR+ cancer cells over a healthy cell population (EGFR−).
Furthermore, a notable cytotoxic eﬀect on the cancer cells was
observed upon application of an alternating magnetic field
(83 kA m−1 and 220 kHz). After the primary work by Büchner and
coworkers,43 this has represented the first report about the bio-
technological potential of Fe@CNTs as a versatile scaﬀold for
in vitro MFH therapy. Exploiting the chemical vapour depo-
sition methodology and post-synthetic treatments (mineral
acid44,45 or thermal46–48), in this work we comprehensively
describe the preparation and the magnetic-dependent physical
properties of Fe-filled CNTs that diﬀer in the Fe content (20 to
35 wt%) and crystalline phase (α-Fe, Fe3C, γ-Fe2O3 and γ-Fe).
The structural, morphological and magnetic properties were
characterized by X-ray photoelectron spectroscopy (XPS),
powder X-ray diﬀraction (PXRD), 57Fe-Mössbauer (57Fe-MS),
transmission electron microscopy (TEM), thermogravimetric
analysis (TGA), superconducting quantum interference device
(SQUID) and magnetic and thermal measurements (specific
absorption rate, SAR). Subsequent bioconjugation with cetuxi-
mab led to functional materials for magnetic filtration and
MFH therapy applications, whose eﬃciency resulted to be
dependent on both the content and type of the confined
Fe phases.
2. Results and discussion
2.1 Synthesis and physicochemical characterization of
Fe@CNTs
The FC-CVD process uses organometallic compounds, such as
ferrocene49 (Fc) or cobaltocene,50 serving as both metal and
carbon atom sources, with or without a complementary carbon
feedstock. These organometallic species form metallic nano-
particles at high temperature (>600 °C) that catalyse the
growth of MNPs@CNTs. During this process, the MNPs
undergo spontaneous encapsulation into graphitic nano-
particles.51,52 Among the multitude of the FC-CVD methods
for growing CNTs,38,49,50,53–73 significant structural and com-
positional diﬀerences exist in terms of length, diameter,
number of walls, MNP loading, chemical composition, crystal-
linity, and morphology. As a general trend, the FC-CVD
technique produces structurally homogeneous Fe@CNTs,74
displaying limited amounts of Fe (2–10 Fe wt%, with Ms values
below 10 emu g−1)43 when complementary carbon feedstock
like EtOH, toluene or acetylene is used.41,63,72,75 On the other
hand, protocols employing only Fc lead to structurally-
inhomogeneous Fe@CNTs, with higher Fe loadings (up to
50 wt%) and enhanced Ms values (between 40 and 60 emu
g−1).53,59,76 Literature studies showed that the temperature of
Fc-sublimation (Tsub)
53,76 and synthesis (Tsynth)
76 are crucial
for controlling the morphology of the material. Too low Tsub
(<160 °C) leads to the preferential formation of core–shell
nanoparticles, in which the Fe phases are wrapped in several
graphitic layers (Fe@CNPs).53
Based on these literature premises, we prepared Fe@CNT
hybrids possessing diﬀerent Fe contents using the FC-CVD
protocol with Fc sublimation either at 350 °C (Fc-Fe@CNTs,
Scheme 1) or at 550 °C with toluene as a complementary
source of carbon (Tol-Fe@CNTs). We thus evaluated the
amount and quality of the exohedrally- and endohedrally-
confined Fe phases through a combination of macroscopic
(TGA, XPS, EDX, PXRD and 57Fe-MS analysis) and microscopic
(TEM) techniques.
TGA analyses of Fc-Fe@CNTs and Tol-Fe@CNTs displayed
remarkable Fe loadings of about 36 and 24 wt%, respectively
(Table 1 and Fig. 1.2a–d). As the XPS investigations only dis-
played the presence of C and O binding energies, the spectra
revealed only minor amounts of Fe (0.8 ± 0.2 at% for
Fc-Fe@CNTs and 0.3 ± 0.0 at% for Tol-Fe@CNTs), thus
suggesting that only traces of Fe are present at the exosurface
of the nanotubes. While both metallic and oxidised Fe par-
ticles are observed for Fc-Fe@CNTs (peaks centred at 707 and
712 eV, respectively, Fig. 1.3a–d), only metallic phases are
present in Tol-Fe@CNTs (Fig. 1.3d). TGA profiles under air
(Fig. 1.2a–d) displayed the presence of a 4 wt% increase before
the graphitic oxidation event (at about 480 °C) for the samples
containing Fc-Fe@CNTs (Fig. 1.2a), thus suggesting the
formation of Fe oxides most likely derived from non-fully
Scheme 1 Synthetic routes for the preparation of magnetic Fe@CNTs.
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encapsulated Fe phases. 57Fe-MS (Fig. 1.1a–d) and PXRD spectra
(Fig. S1†) displayed the presence of four Fe phases for
Fc-Fe@CNTs (Fe3C, and lower amounts of α-Fe, γ-Fe and
γ-Fe2O3) and essentially Fe3C with some traces of γ-Fe for
samples containing Tol-Fe@CNTs (Fig. 1.1d). Given the recent
discoveries about the seeding role of Fe3C particles in the
growth of CNTs,77 we can reasonably think that Fe3C NPs are
initially formed and subsequently govern the CNT growth.
Consequently, the high loading of Fe3C found in the
Tol-Fe@CNT samples is most likely derived from the higher
C/Fe ratio of the feedstock (i.e., toluene/Fc) during the CVD
process compared to the conditions used for Fc-Fe@CNTs.
To remove the non-encapsulated Fe, Fc-Fe@CNTs were
washed several times with an aqueous HCl solution
(Scheme 1). This enabled a stepwise reduction of the Fe
loading after the first and the second washing cycles, produ-
cing HCl-Fe@CNTs displaying 19 wt% of Fe as determined by
TGA (Fig. 1.2b). Notably, a strong decrease in both α-Fe and
γ-Fe2O3 phases was observed, leading to samples enriched in
Fe3C as measured by
57Fe-MS (Fig. 1.1b), PXRD (Fig. S1†) and
XPS (Fe 2p peak disappearance in the XPS spectrum after
washing Fig. 1.3b). These acid-induced changes of both com-
position and crystallinity of the Fe phases have also been pre-
viously reported in the literature.44 Aiming at increasing the
content of the α-Fe phase by thermal disproportionation of
Table 1 Fe compositional assessment as determined by XPS, 57Fe-MS
and TGA under air
Hybrid
XPS
(at% ± SD)
TGA under
air (wt%)
57Fe-MS (abundance (%))
Fe3C α-Fe γ-Fe γ-Fe2O3
Fc-Fe@CNTs 0.8 (±0.2) 35.8 76 10 5 9
HCl-Fe@CNTs 0.2 (±0.0) 19.0 88 5 7 0
Ann-Fe@CNTs — 22.1 54 44 2 0
Tol-Fe@CNTs 0.3 (±0.0) 23.8 98 0 2 0
Fig. 1 (1) 57Fe-Mössbauer, (2) TGA under air and (3) Fe 2p XPS proﬁles for (a) Fc-Fe@CNTs, (b) HCl-Fe@CNTs, (c) Ann-Fe@CNTs and (d) Tol-
Fe@CNTs. In the 57Fe-Mössbauer spectra (1a–d), the singlet is assigned to paramagnetic γ-Fe (blue colour); the sextet with δ = 0.19(1) mm s−1, quad-
rupole shift ε = 0.01(1) mm s−1 and hyperﬁne magnetic ﬁeld (Bhf ) of 20.6 T corresponds to Fe3C (green colour); the sextet with zero isomer and
quadrupole shifts indicates a cubic symmetry (Bhf = 33.1 T), typical for ferromagnetic α-Fe (red colour); the sextet with δ = 0.34(6) mm s−1, ε = 0.05
(6) mm s−1 and Bhf = 48.3(4) T indicates the presence of traces of γ-Fe2O3 (pink colour). Hyperﬁne parameters are gathered in Table S1.† The TGA
proﬁles are displayed as temperature-modulated weight% (—) and diﬀerential weight% ( ) (2a–d). The red square indicates a pronounced weight
gain before the pyrolysis event in Fc-Fe@CNTs. XPS high-resolution spectra (3a–d) show the presence of oxidised (blue triangles) and metallic
(green stars) Fe 2p peaks, both attributed to the most superﬁcial Fe phases.
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Fe3C, α-Fe-enriched samples were prepared by adaptation of
literature protocols.47,48 HCl-Fe@CNTs were heated at 580 °C
under an Ar/H2 flow for 15 h to aﬀord annealed Fe-filled CNTs,
Ann-Fe@CNTs (Scheme 1). Notably, the annealing protocol
caused a slight increase in the total Fe ratio (from 19 to 22 wt%,
Fig. 1.2b and 2), and a considerable enrichment of the α-Fe
phase (from 5% to 44% of α-Fe, Fig. 1.1c and 2). It should be
pointed out that the complete conversion of Fe3C into α-Fe is
diﬃcult to accomplish, since it requires temperatures at which
the decomposition of the graphitic layers could occur.78,79
Fig. 2 shows a graphical representation of the amount of Fe
phases in our set of Fe@CNT derivatives.
Regarding the morphological characterization, low-resolu-
tion TEM investigations of Fc-Fe@CNTs (Fig. 3) allowed us to
distinguish two categories of Fe@CNTs: those initially pro-
duced using ferrocene only during the CVD process
(Fc-Fe@CNTs, HCl-Fe@CNTs and Ann-Fe@CNTs) are relatively
short (modal classes of 0.4 to 0.6 µm in length and 5–10 nm in
diameter according to the frequency histograms depicted in
Fig. S2†) whereas those produced from a mixture of toluene
and ferrocene (Tol-Fe@CNTs), are longer and wider (modal
class of 1.4 to 1.6 µm in length and 25–30 nm in diameter).
Importantly, no significant morphological diﬀerences have
been observed and measured between the samples containing
Fc-Fe@CNTs, HCl-Fe@CNTs and Ann-Fe@CNTs, suggesting
that the main structural features of CNT nanostructures were
preserved during the acidic washings and annealing treat-
ments (Fig. 3a–c and S2†). On the other hand, the diﬀerent
size distribution of Tol-Fe@CNTs is probably due to a sup-
plementary supply of carbon during their growth.
Regarding the Fe nanoparticles, those located at the tips of
the CNTs are large spherical particles (between 20 and 70 nm)
while conversely, the particles buried in the tubular cavities
generally have the shape of nanorods (length up to 500 nm).
This observation correlates well with the Fe encapsulation
mechanism proposed by Kim et al. in which the iron layer in a
growing carbon nanotube may be pinched oﬀ and forms dis-
continuous elongated iron particles inside the cavity.80
Notably, core–shell Fe nanoparticles (Fe@CNPs) have also
been observed, in which the graphitic layers wrap the spherical
Fe phases in an onion-like fashion (Fig. 3a). Interestingly, the
TEM images of HCl-Fe@CNTs (Fig. 3b and S3†) show a
reduced content of the more spherical Fe@CNPs, while the
elongated Fe rods confined in the CNTs seem unaltered,
which is reflected in the frequency histograms of Fe particle
size and aspect ratio distributions (Fig. S4†). These obser-
vations suggest that Fe@CNPs can be altered under acidic con-
ditions, and thus easily removed with several washing cycles.
Interestingly also, the Fe particles seemed to contract during
annealing, taking smaller and more spherical shapes (the
modal class of Fe particle dimensions passing from 30–40 nm
in HCl-Fe@CNTs to 10–20 nm in Ann-Fe@CNTs, Fig. S4†).
These observations are consistent with those of Kim et al. who
remarked a similar “contraction” phenomenon occurring
during the heating of their γ-rich Fe@CNTs at elevated temp-
eratures (above 900 °C).81
High-resolution TEM (HR-TEM) studies were used to inves-
tigate the morphology and the phase of both exohedral and
endohedral Fe-based nanostructures (Fig. 4). As already
observed by LR-TEM, HR-TEM analyses further confirmed the
presence of encapsulated Fe particles both as spherical and
rod-like nanostructures surrounded by graphitic shells
(d-spacing of 0.34 nm). The HR-TEM investigations carried out
on several spheroidal/polygonal Fe nanostructures in
Fc-Fe@CNTs and HCl-Fe@CNTs (Fig. 4a and b), shed further
light on the crystallographic properties of the Fe nano-
structures. In particular, as anticipated by the PXRD and
57Fe-MS measurements (Fig. S1, 1.1a and b†), Fe3C is the most
abundant phase.
However, due to a subtle diﬀerence in the lattice spacing
between the (011)-planes of α-Fe, (111)-planes of γ-Fe and
(102)-, (220)-, (031)- and (112)-planes of Fe3C (respectively of
2.03, 2.07, 2.07, 2.03, 2.01 and 1.97 Å), it is diﬃcult to dis-
tinguish the γ-Fe, α-Fe and Fe3C phases (Fig. 4a and Table S2†)
when the three phases coexist. It is also noteworthy to
mention that neither any particular crystal segregation
between exohedral and endohedral Fe nanostructures nor pre-
ferential crystal plane alignments were observed in our
samples, in contradiction with the observations of Kim et al.
made on γ-Fe rich Fe@CNTs.81
The magnetic properties of the four Fe@CNT materials
were assessed by recording hysteresis curves at 300 K, which
allowed for the calculation of the magnetic saturation (Ms),
coercivity (Hc) and low-field magnetic susceptibility (χ) values
(Fig. 5 and S5, Tables 2 and S3†). In the case of the Fe3C-
enriched Fe@CNT derivatives, the Ms values decrease in the
following order: Fc-Fe@CNTs > Tol-Fe@CNTs > HCl-Fe@CNTs.
This clearly correlates to the Fe content. On the contrary, if
one compares CNTs containing similar amounts of Fe, namely
HCl-Fe@CNTs and Ann-Fe@CNTs, the Ms (higher for α-Fe)33
and the coercivity (higher for Fe3C)
82 of diﬀerent ferro-
magnetic phases have also to be considered. In this respect,
Fig. 2 Histogram distribution of the Fe phases in the four materials as
assessed by 57Fe-Mössbauer spectroscopy and TGA measurements
under air.
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samples containing Ann-Fe@CNTs display the highest Ms
(34 vs. 24 emu g−1) and the smallest coercivity (430 vs. 570 Oe)
as a consequence of the high α-Fe/Fe3C ratio.83 A moderate
increase in the Hc value was also observed for the HCl-washed
samples (from 550 to 570 Oe for Fc-Fe@CNTs and HCl-
Fe@CNTs, respectively), caused by the significant loss of the
exohedral Fe nanoparticles and the presence of the aniso-
tropic, and thus highly coercive, endohedral Fe nanorods.71
2.2 Bioconjugation and physicochemical characterization
For the exohedral functionalization of the Fe@CNTs, we fol-
lowed the covalent approach developed by Tour and co-
workers.84 We have selected the trimethylsilylethoxycarbonyl
(Teoc) group for 4-aminobenzylamine 1 protection, as its
removal does not require acidic treatments that could interfere
with the Fe content and crystallinity. Teoc-protected amino-
benzylamine 2 was thus prepared and reacted with the selected
Fe@CNTs in the presence of isoamyl nitrite (Scheme 2),
aﬀording the functionalized material, Fe@CNT–NHTeoc.
The cleavage of the Teoc group using tetrabutylammonium
fluoride (TBAF) aﬀorded Fe@CNT–NH2 that, under typical
amide ligation coupling conditions using EDC,39,85 was trans-
formed into Fe@CNT–Ab in the presence of the antibody. The
intermediates were characterized by XPS, which revealed peaks
at 101 and 400 eV for Fe@CNT–NHTeoc, attributed to the Si 2p
and N 1s binding energies of the Teoc and amine groups,
respectively (Fig. 6, columns 1 and 2, and S6–9†). TGA analysis
under a N2 atmosphere clearly shows a pyrolysis event in the
range between 200 and 400 °C, suggesting a functionalization
degree between 2 and 4 wt% for Fe@CNT–NH2 (Fig. 6, column 3,
Fig. 3 Bright-ﬁeld TEM images at diﬀerent magniﬁcations of the Fe@CNT derivatives as deposited from a suspension (0.1 mg mL−1) onto Cu grids:
(a) Fc-Fe@CNTs, (b) HCl-Fe@CNTs, (c) Ann-Fe@CNTs and (d) Tol-Fe@CNTs.
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and S10†). Notably, TGA analysis under air shows similar
Fe loading for the as-produced and the functionalized
Fe@CNTs (Fig. S11†).
The XPS spectra of the samples after bioconjugation reveal
a dramatic increase of both the oxygen (O 1s at 533 eV) and
nitrogen atom content. The TGA plots of the bioconjugates
show the typical protein signature at 350 °C (Fig. S10†)
suggesting an average 20 wt% loading, and a Fe content of 30,
20, 16 and 15 wt% for Fc-, Tol-, HCl- and Ann-Fe@CNT–Ab,
respectively (Table S5†).
2.3 In vitro magnetic performances
2.3.1 Magnetic cell filtration. The response of the
Fe@CNT–Ab derivatives to a static magnetic field gradient is
an important parameter if one wants to use them as a cell
sorting device86,87 and/or for filtration of biologically relevant
species.88,89 For this measurement, we have prepared water
dispersions containing a given Fe@CNT–Ab derivative (at an
equivalent Fe concentration of 30 µg mL−1) and recorded the
time-dependent UV-vis absorbance in the presence of a mag-
netic field gradient (Fig. 7a). The natural sedimentation of our
materials was followed by the same method but in the absence
of a magnet. Defining the “coagulation eﬀectiveness” (CE) as
the proportion of Fe@CNT–Ab removed from the water dis-
persion at a given time, one can calculate the CE(t ) value fol-
lowing eqn (1):
CE tð Þ ¼ 1 Absorbance tð Þ  Absorbance blankð Þ
Absorbance t ¼ 0ð Þ  Absorbance blankð Þ
 
 100 ðin %Þ ð1Þ
Fig. 4 HR-TEM images of the Fe nanostructures in (a) Fc-Fe@CNTs, (b) HCl-Fe@CNTs and (c) Ann-Fe@CNTs. FFT and direct distance measurements
on some selected regions (orange rectangles) were used to estimate the inter-lattice distance value. For Fc-Fe@CNTs and HCl-Fe@CNTs, the typical
Fe3C cementite crystal lattice was observed, whereas for Ann-Fe@CNTs (c) α-Fe phases were also found. The corresponding lattice parameters are
indexed directly on the image. Scale bar = 10 nm.
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Fig. 5 Magnetization curves for the four Fe@CNTs substrates, (a) full traces (from −60 to +60 kOe) and (b) zoomed region (from −2 to +2 kOe).
Table 2 Magnetic parameters (Ms, Hc, χ and area of the hysteresis loop) for the four Fe@CNT hybrids
Hybrid Ms (emu g
−1) Ms (emu g
−1 Fe) Hc (Oe) χ (emu Oe
−1 g−1)
Þ
M  H ðemukOe g1Þ ÞM H ðemukOe g1 FeÞ
Fc-Fe@CNTs 48 134 550 0.0216 63.18 176.5
HCl-Fe@CNTs 24 126 570 0.0118 36.05 189.7
Ann-Fe@CNTs 34 153 430 0.0174 24.08 108.9
Tol-Fe@CNTs 33 139 550 0.0165 45.14 189.7
Scheme 2 Synthetic routes for the bioconjugation of Fe@CNTs.
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The CE trend in the presence of a magnetic field suggests
that the bioconjugates prepared from Fc-Fe@CNTs and Tol-
Fe@CNTs behave similarly, whereas HCl-Fe@CNT–Ab and
Ann-Fe@CNT–Ab are less eﬀective as they display lower coagu-
lation values. One can notice that this trend is very similar to
that obtained in the absence of a magnetic field gradient,
meaning that the dispersibility of our materials is the primary
cause of their magnetic coagulation eﬀectiveness. Their disper-
sibility most probably depends on the magnetic characteristics
of the given Fe@CNTs, with those featuring the highest Fe
loadings and the most coercive phase being the fastest to
coagulate. In a subsequent experiment we have interfaced the
four Fe@CNT–Ab bioconjugates with A431 cells, a model of
epidermoid cancer cells over-expressing the epithelial growth
factor receptors (EGFR) targeted by cetuximab.39 Defining the
“cell fishing eﬀectiveness” (CFE) as the time-
dependent population of cells remaining in a solution
upon application of a given static magnetic field gradient
(Fig. 7b and 8), one can also calculate the CFE(t ) value defined
as eqn (2):
CFE tð Þ ¼ 1 Cell density tð Þ
Initial cell density
 
 100 in%ð Þ ð2Þ
From these measurements, it clearly appears that the best
performing derivative is HCl-Fe@CNT–Ab, followed by Tol-,
Ann- and finally Fc-Fe@CNT–Ab. This contrasts with the CE
trend observed in the absence of the cells. Whereas the CE
value reflects the properties of the material in the absence of
the cells (it depends on the Fe loading and phase), the CFE
analysis measures the eﬃciency to shepherd cells, thus
embracing a complex system in which the bioconjugates are
linked to a cell. This suggests that the Ab/Fe weight ratio also
has to be accounted for the rationalisation of the data
(Table S5†). As both the Fe concentration and the A431 cell
density were constant, the CFE values clearly shows that
the HCl-Fe@CNT–Ab and Tol-Fe@CNT–Ab bioconjugates
Fig. 6 High-resolution XPS spectra ((1) Si 2p and (2) N 1s) and (3) TGA under nitrogen proﬁles (temperature-modulated weight% (—) and diﬀerential
weight% ( )) for reference (a) Teoc-benzylamine 3, (b) Ann-Fe@CNTs, (c) Ann-Fe@CNT–NHTeoc, (d) Ann-Fe@CNT–NH2 and (e) Ann-Fe@CNT–Ab.
The 101 eV peak (green star) ﬁngerprints the Teoc protecting group, whereas the peak at 103 eV (black triangle) is attributed to a SiO2 impurity.
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were the most eﬀective materials, whereas Fc-Fe@CNT–Ab
classified last and Ann-Fe@CNT–Ab displayed an intermediate
behaviour. These data show that bioconjugates possessing
high Ab/Fe ratios ensure a more eﬃcient cellular binding,
enhancing the shepherding action. Most likely, the diﬀerence
between the Ann-Fe@CNT–Ab and HCl-Fe@CNT–Ab can be
ascribed to the presence of phases displaying diﬀerent coerciv-
ity values.
In parallel, the role of the antibody was assessed via a mag-
netic cell fishing using the best candidate HCl-Fe@CNT–Ab
onto a control EGFR− cell line, i.e. EAhy926 (EA) cells. As
expected, a remarkable reduction (25 vs. 75% after 1 min and
Fig. 7 (a) Time-dependent coagulation eﬀectiveness for the Fe@CNT–Ab derivatives in the presence (upper curves) or in the absence (lower
curves) of a magnet. The results are expressed as means ± 1 S.D. (n = 3, in the presence of a magnet and n = 1 in the absence of a magnet). (b) Mag-
netic cell ﬁltration eﬀectiveness of the Fe@CNT–Ab derivatives on A431 or EA cells. The results are expressed as means ± 1 S.D. (n = 3).
Fig. 8 Optical microscopy images displaying the cell content after (1) 0, (2) 60, (3) 120, (4) 240, (5) 480 seconds of magnetic ﬁshing of A431 cells
using (a) Fc-Fe@CNT–Ab, (b) HCl-Fe@CNT–Ab, (c) Ann-Fe@CNT–Ab or (d) Tol-Fe@CNT–Ab and ﬁshing of EA cells with (e) HCl-Fe@CNT–Ab. Scale
bar = 250 µm (all the images are at the same scale).
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50 vs. 99% after 8 minutes, Fig. 7b and 8e) of the Cell Fishing
Eﬀectiveness (CFE) was observed, demonstrating the crucial
role of the antibody as an anchoring unit toward EGFR+ cells.
The intriguing relatively high percentage of EA cells neverthe-
less fished suggests the presence of a certain degree of aspeci-
fic binding. In order to know if this could hamper any
selective removal of EGFR+ vs. EGFR− cells in a mixture of
these two cell lines, EA and A431 cells were fluorescently
stained in two diﬀerent colours (red for A431 and green for
EA), mixed together with HCl-Fe@CNT–Ab and placed against
a magnet for 8 minutes (Fig. 9). The quasi-absence of A431
(red) cells remaining in the supernatant after this period of
time along with a clear surrounding of A431 cells by CNTs in
the precipitate indicate that selective binding occurs, allowing
selective removal of the targeted EGFR+ cells over the non-
targeted EGFR− cells. However, the presence of EA (green)
cells in the magnetically-induced precipitate along with the
observation of fewer black areas around some EA cells suggests
the existence of a certain degree of non-specific binding of our
CNTs towards these cells.
2.3.2 Magnetic fluid hyperthermia. Ferromagnetic par-
ticles exposed to an alternating magnetic field dissipate heat
by hysteresis loss, and the dissipation eﬃciency of such heat is
measured by the specific absorption rate (SAR) per mass of
heating material, defined as eqn (3):90,91
SAR ¼ mi
me
 dT
dt
 
 ci ðWg1Þ ð3Þ
where ci is the specific heat capacity of the fluid, mi is the total
mass of the fluid, me is the mass of the heating material and
dT/dt is the evolution of temperature of the ferrofluid as a
function of time. The related heat generation can determine
both the microscopic and bulk heating, and thus be exploited
to aﬀect cell viability by initiating cell death by apoptosis or
necrosis.27,92 We thus measured the SAR values of our set of
Fe@CNT–Ab bioconjugates at a constant Fe concentration of
125 µg mL−1 in a complete cell medium (whose ci was approxi-
mated to 4.185 J g−1 K−1), using alternating magnetic fields
(220 kHz and amplitude in the range of 45–75 kA m−1) and
recording the temperature evolution over time (Fig. S12†).
Being under non-adiabatic conditions, dT/dt values were
obtained by performing a Box Lucas exponential fitting of the
T vs. t curve and then calculating the slope dT/dt at t0 as
reported in the literature.93 The experimental SAR values of
our CNT-based bioconjugates range from a minimum of 300
W g−1 at 45 kA m−1 to a maximum around 2000 W g−1 at 75 kA
m−1, showing some pronounced diﬀerences depending on the
Fe content and phase crystallinity (Fig. 10).
For ferromagnetic particles, SAR is mainly caused by hyster-
esis loss and it can be estimated from the following equation
(eqn (4)):43
SAR ¼ μ0  f 
þ
M  H ð4Þ
with μ0 being the vacuum magnetic permeability, f the fre-
quency (Hz), and
Þ
M  H the area of the hysteresis loop
(Fig. 5 and Table 2). The whole hysteresis area is obtained only
when the magnetic field (H) is higher than the saturation field
that, for our Fe@CNT derivatives, is around 20 kOe, corres-
ponding to the amplitudes of about 1600 kA m−1. Since during
the SAR measurements we used a dynamic field with ampli-
tudes up to 75 kA m−1, it is very likely that we did not fully
Fig. 9 Confocal microscopy images of (a) an initial mixture of HCl-Fe@CNT–Ab, A431 (red) and EA (green) cells and of (b) the supernatant and (c) the
coagulate after 8 minutes of magnetic ﬁltration. Black arrows indicate the presence of HCl-Fe@CNT–Ab aggregates, preferentially around A431 cells.
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exploit the hysteresis loss. This suggests that the theoretical
SAR values (SARth, calculated from eqn (4) using the SQUID
analysis), are likely to be bigger than those obtained experi-
mentally (SARexp, Table 3). Interestingly, the SARexp/SARth
ratios of Fc-, Tol- and HCl-Fe@CNT–Ab are very similar, while
Ann-Fe@CNT–Ab displayed a higher ratio. This discrimination
well correlates with the lower coercivity and hysteresis area of
Ann-Fe@CNT–Ab compared to those of the other bioconju-
gates. It should be pointed out that a similar trend of inverse
proportionality between the coercivity and SAR values was
already observed for ferromagnetic Fe3O4 nanoparticles by
Ma et al.94
In order to compare the performances of our materials with
commercially available Fe MNPs, we used a system-indepen-
dent parameter introduced by Kallumadil et al.93 called the
Intrinsic Loss Power (ILP), defined as (eqn (5)):
ILP ¼ SAR
Hf
ð5Þ
with H being the external magnetic field strength applied
(A m−1) and f the frequency (Hz). Compared to other Fe MNPs,
the hyperthermia performances of our Fe@CNTs can be
grouped in the upper range, since on 16 diﬀerent commercial
MNPs analysed by Kallumadil et al.93 only four (100 and
130 nm Micromod’s Nanomag-D-spio, Bayer’s Resovist and
Chemicell’s FluidMAG-D) showed higher ILP values (respect-
ively 3.12, 2.31, 3.1 and 2.67 nH m2 kg−1) than our best candi-
date Tol-Fe@CNTs (2.05 nH m2 kg−1).
In vitro magnetic fluid hyperthermia studies were then per-
formed by suspending the EGFR+ overexpressing A431 cells
and the chosen Fe@CNT–Ab at a constant Fe concentration of
125 µg mL−1. To avoid bulk overheating, we thermostated the
suspension and used pulsed magnetic fields (40 seconds per
minute for 30 minutes, Fig. 11a). It is important to note that,
to the best of our knowledge, the idea of using pulsed mag-
netic fields is quite recent. In particular, Rosania and co-
workers recently demonstrated the advantage of this approach
to improve the transport of iron oxide nanoparticles through
cell barriers.95 In our case, the pulses allow us to take an
advantage of the high hyperthermic potential of our coercive
Fe@CNTs at high fields (85 kA m−1) without damaging non-
targeted cells.
For each MFH test, the cell mortality was assessed by
trypan blue staining and was accompanied by three negative
controls (cells mixed or not mixed with Fe@CNT–Ab isother-
mally kept at 37 °C and cells exposed to the pulsed magnetic
field conditions without Fe@CNTs) and one positive control
(cells maintained at 70 °C). It emerged that HCl-Fe@CNT–Ab
has significantly better hyperthermia activity (induction of
around 70% mortality) than the other derivatives, which
induced a cell death ranging from 15% to 40% (Fig. 11c). The
comparison between HCl- and Ann-Fe@CNT–Ab is of particu-
lar interest since the two materials mainly diﬀer in the Fe3C/
α-Fe ratio. As expected, the higher the proportion of the Fe3C
phase, the higher the SAR, and thus the hyperthermia
eﬃciency. On the other hand, Fc- and Tol-Fe@CNTs are the
least cytotoxic, probably due to the lower CNT concentration
necessary to keep the same Fe concentration. This finding is
of particular importance, as it suggests that a good balance
between the Fe loading per nanotube and total concentration
of CNTs is necessary if one wants to maximize the cytotoxic
action of these hybrids.
Finally, the role of the antibody in the MFH-induced cyto-
toxic eﬀect was performed using our best material, i.e. HCl-
Fe@CNT–Ab, onto EA cells instead of A431 cells, all other para-
meters being kept identical (Fig. 11c, 12th and 13th bars).
Table 3 Theoretical (SARth) and experimental (SARexp) SAR values at
220 kHz and 75 kA m−1 for the four Fe@CNT hybrids
Hybrid SARth (kW g
−1 Fe) SARexp (kW g
−1 Fe) SARex/SARth
Fc-Fe@CNTs 3.88 1.96 0.50
HCl-Fe@CNTs 4.17 2.04 0.49
Ann-Fe@CNTs 2.40 1.51 0.63
Tol-Fe@CNTs 4.18 2.00 0.48
Fig. 10 (a) SAR at diﬀerent magnetic ﬁeld strengths and (b) ILP values for the four Fe@CNT–Ab.
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A severe reduction (15% for EA cells vs. 70% for A431 cells) in
mortality rates was observed, confirming the crucial role of the
antibody in the surrounding of the targeted cell membranes,
leading to an eﬃcient local heating eﬀect and in fine cell
death.
3. Conclusion
Using a combination of CVD and post-synthetic annealing pro-
tocols, we have successfully prepared a series of Fe@CNTs fea-
turing diverse Fe phases and loadings in a controlled fashion.
These materials undergo diﬀerent responses under either
static or dynamic magnetic fields depending on the magneto-
crystalline characteristics of the inner metal phases. For
instance, MFH experiments revealed that Fe@CNTs containing
greater amounts of the more coercive Fe3C phase display
higher SAR values (∼2 kW g−1 Fe) when compared to samples
enriched in α-Fe (∼1.5 kW g−1 Fe) at high fields (75 kA m−1).
Successive organic functionalization of the exohedral graphitic
layer, followed by conjugation with a cancer-cell targeting anti-
body, yields bioactive Fe@CNT–Ab hybrids. It has been shown
that these hybrids allow a rapid (after a few minutes) and very
selective catching of a population of cancer cells over healthy
Fig. 11 (a) Timeline of the pulsed MFH conditions (40 s of impulse each minute for 30 minutes). (b) Phase contrast microscopy images of EGFR+
A431 cells after “pulsed” MFH incubation with Fc-Fe@CNT–Ab (1), HCl-Fe@CNT–Ab (2), Ann-Fe@CNT–Ab, (3) Tol-Fe@CNT–Ab (4) and with conven-
tional heating at 37 °C (5) and at 70 °C (6). After the incubation, cells were stained with trypan blue. Scale bar = 50 µm. (c) Cell death as assayed with
trypan blue staining; the results are expressed as means ± 1 S.D. (n = 3). ANOVA-2 (Holm–Šídák method): ***: p < 0.001, **: p < 0.01 and n.s.:
p > 0.05. For comparisons for factors Fe@CNTs within “+MFH” and for Fe@CNTs within “−MFH”, conditions with diﬀerent letters (on top of the bar)
have signiﬁcantly diﬀerent means (p < 0.05).
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ones and are able to provoke their death (up to 70%) upon
applications of pulsed MFH treatments. Specifically, it has
been found that an ideal ratio of 1.2 Ab/Fe is necessary to
eﬃciently interface with the cellular bodies facilitating their
removal. In agreement with the SAR values, the hybrids con-
taining higher percentages of Fe3C for a given Fe/C ratio
display higher cytotoxicity levels using our MFH protocol.
Moreover, at an equivalent Fe concentration, higher cytotoxic
eﬀects were observed for the nanotubes exhibiting lower Fe/C
ratios. These observations suggest that an optimal combi-
nation between the total amount of Fe, the type of Fe phase
and the Ab loading is needed to prepare eﬃcient Fe@CNTs for
the magnetic-triggered biomedical applications. In particular,
we think that a synergistic eﬀect between the Ab loading and
the Fe distribution in each kind of Fe@CNT exists, for which
the maximum shepherding and hyperthermia eﬀects are
observed when higher densities of Fe@CNTs featuring the
more coercive phase are interfaced with the cells.
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